| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/09/2011 | EP2281588A1 Semi-synthetic platelet gel and method for the preparation thereof |
| 02/09/2011 | EP2281569A1 Use of prourokinase and variants thereof in facilitated percutaneous coronary intervention in patients with acute myocardial infarction |
| 02/09/2011 | EP2281568A2 Uses of soluble CTLA4 mutant molecules |
| 02/09/2011 | EP2281566A1 Synergic 5'-methylthioadenosine combinations |
| 02/09/2011 | EP2280996A2 AFFINITY MATURED CRIg VARIANTS |
| 02/09/2011 | EP2280995A2 Methods for treating inflammation |
| 02/09/2011 | EP2280994A1 Restoration of estrogen receptor-alpha activity |
| 02/09/2011 | EP2280989A2 Cyclosporin analogs and their use in the treatment of hcv infections |
| 02/09/2011 | EP2280988A2 Angiogenic peptide |
| 02/09/2011 | EP2280734A2 Factor ix conjugates with extended half-lives |
| 02/09/2011 | EP2280726A1 Anti-viral nutraceutical |
| 02/09/2011 | EP2280722A2 Method of treating degenerative diseases |
| 02/09/2011 | EP2280721A1 Indoleamine 2, 3-dioxygenase based immunotherapy |
| 02/09/2011 | EP2280720A2 Collagen-binding synthetic peptidoglycans, preparation, and methods of use |
| 02/09/2011 | EP2280719A2 Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy |
| 02/09/2011 | EP2280716A1 Agents and methods for treatment of anxiety disorders |
| 02/09/2011 | EP2280709A1 Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin |
| 02/09/2011 | EP2280693A2 Liquid and freeze dried formulations |
| 02/09/2011 | EP2137209B1 Compounds for the diagnosis of diseases associated with vcam expression |
| 02/09/2011 | EP2057184B1 Cyclic angiotensin analogs |
| 02/09/2011 | EP1973561B1 Enzymes for reduced immunological stress |
| 02/09/2011 | EP1970380B1 Inhibitor of the uracil-dna glycosylase enzyme and uses thereof |
| 02/09/2011 | EP1947111B1 Mucin glycoprotein and use thereof |
| 02/09/2011 | EP1931656B1 Novel drugs for dementia |
| 02/09/2011 | EP1885754B1 T cell receptors which specifically bind to vygfvracl-hla-a24 |
| 02/09/2011 | EP1877439B1 Il-21 variants |
| 02/09/2011 | EP1874140B1 Peptides having a health benefit and compositions comprising them |
| 02/09/2011 | EP1778272B1 Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv) |
| 02/09/2011 | EP1750808B1 Myricitrin compounds for treating sleeping disorders |
| 02/09/2011 | EP1722813B1 Cosmetic or therapeutic use of botulinum toxin for preventing hair growth |
| 02/09/2011 | EP1716869B1 Drug for preventing or treating heart diseases comprising cd9 gene |
| 02/09/2011 | EP1648931B1 Multifunctional cytokines |
| 02/09/2011 | EP1636561B1 Combinatorial protein library screening by periplasmic expression |
| 02/09/2011 | EP1585538B1 Non-hypertensive pegylated hemoglobins and methods of preparation thereof |
| 02/09/2011 | EP1573046B1 Protease resistant ti-growth hormone releasing hormone |
| 02/09/2011 | EP1545587B1 Lactoferrin compositions and methods of diabetic ulcer treatment |
| 02/09/2011 | EP1504098B2 A method for in vitro molecular evolution of protein function |
| 02/09/2011 | EP1459738B1 Pharmaceutical composition having thrombolytic, anti-inflammatory and cytoprotective properties |
| 02/09/2011 | EP1381385B1 Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability |
| 02/09/2011 | EP1370276B1 Intercellular communication facilitating compounds and their medical use |
| 02/09/2011 | EP1280898B1 Modified es cells and es cell-specific gene |
| 02/09/2011 | EP1181313B1 Peptides for vaccinating against human cmv |
| 02/09/2011 | EP1100929B1 Identification and functional characterization of a novel ribosomal s6 protein kinase |
| 02/09/2011 | EP0986577B1 Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| 02/09/2011 | EP0848755B2 Vegf-related protein |
| 02/09/2011 | EP0771324B2 Concentrate of fibrinogene obtained from blood plasma, process and plant for its preparation |
| 02/09/2011 | EP0668777B2 Prostate-specific membrane antigen |
| 02/09/2011 | CN1953765B An agent comprising FGF2 as an effective ingredient for treatment or prevention of asthma and chronic obstructive pulmonary disease |
| 02/09/2011 | CN1889937B Glycopegylated factor IX |
| 02/09/2011 | CN1827638B Vancomycin and nor-vancomycin derivatives and their preparation process and use |
| 02/09/2011 | CN1799631B Animal model for fetal alcohol syndrome and methods of treatment |
| 02/09/2011 | CN101970678A Biological active proteins having increased in vivo and/or vitro stability |
| 02/09/2011 | CN101970670A Methods for inhibiting angiogenesis using egfl8 antagonists |
| 02/09/2011 | CN101970663A Impaired wound healing compositions and treatments |
| 02/09/2011 | CN101970643A Process for reducing effects of graft versus host disease using ex vivo expanded cd4+cd25+ regulatory t cells |
| 02/09/2011 | CN101970639A Microorganism producing cyclic compound |
| 02/09/2011 | CN101970481A Demannosylated recombinant factor viii for the treatment of patients with hemophiila a |
| 02/09/2011 | CN101970478A Modulation of sirpalphalpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| 02/09/2011 | CN101970477A Protease-stabilized insulin analogues |
| 02/09/2011 | CN101970475A Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour |
| 02/09/2011 | CN101970474A Cyclic, cystein-free protein |
| 02/09/2011 | CN101970468A Component protein pa1698 for type-iii secretion system of pseudomonas aeruginosa |
| 02/09/2011 | CN101970465A Soluble fragments of influenza virus pb2 protein capable of binding rna-cap |
| 02/09/2011 | CN101970464A Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors |
| 02/09/2011 | CN101970462A Cyclic compound and salt thereof |
| 02/09/2011 | CN101970460A Functional lipid constructs |
| 02/09/2011 | CN101970459A Antimicrobial compounds |
| 02/09/2011 | CN101970458A Novel gamma-secretase inhibitor |
| 02/09/2011 | CN101970457A Inhibitors of iap |
| 02/09/2011 | CN101970396A New ruthenium complexes as catalysts for metathesis reactions |
| 02/09/2011 | CN101970013A Novel therapeutical tools and methods for treating blindness |
| 02/09/2011 | CN101970010A Liquid formulation of fsh |
| 02/09/2011 | CN101969996A 多价疫苗 Multivalent vaccine |
| 02/09/2011 | CN101969990A Compositions and methods of enhancinc immune responses to eimeria |
| 02/09/2011 | CN101969989A Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders |
| 02/09/2011 | CN101969986A Radical therapeutic agent for keloid and hypertrophic scar |
| 02/09/2011 | CN101969985A Clottable concentrate of platelet growth factors and preparation method thereof |
| 02/09/2011 | CN101969984A Haemostasis- modulating compositions and uses therefor |
| 02/09/2011 | CN101969983A Method and product for treatment and/or prevention of complications of prematurity |
| 02/09/2011 | CN101969982A Composition for preventing or treating brain diseases |
| 02/09/2011 | CN101969981A Novel crustacean androgenic gland hormone |
| 02/09/2011 | CN101969980A Combination of an anti-edb fibronectin antibody-il-2 fusion protein, and a molecule binding to b cells, b cell progenitors and/or their cancerous counterpart |
| 02/09/2011 | CN101969979A Apoaequorin-containing compositions and methods of using same |
| 02/09/2011 | CN101969978A Compounds and methods for the prevention or treatment of restenosis |
| 02/09/2011 | CN101969976A Polypeptide vaccine and vaccination strategy against mycobacterium |
| 02/09/2011 | CN101969975A Chimeric HIV fusion proteins as vaccines |
| 02/09/2011 | CN101969974A Therapeutic treatment for lung conditions |
| 02/09/2011 | CN101969973A Inhibitors of cathepsin b |
| 02/09/2011 | CN101969972A Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith |
| 02/09/2011 | CN101969971A Protein formulations and methods of making same |
| 02/09/2011 | CN101969970A Combination therapy with antibody-drug conjugates |
| 02/09/2011 | CN101969960A Methods of use of gamma inhibitor compounds for the attenuation of pain |
| 02/09/2011 | CN101969955A Methods of treating thromboembolic disorders |
| 02/09/2011 | CN101969929A Powdered protein compositions and methods of making same |
| 02/09/2011 | CN101969928A Delivery of active agents |
| 02/09/2011 | CN101969927A Method of preventing adverse effects by glp-1 |
| 02/09/2011 | CN101967468A Recombinant human kallidinogenase |
| 02/09/2011 | CN101967196A Interferon fusion protein, preparation thereof and application thereof |
| 02/09/2011 | CN101967195A Thrombolysis-targeting fusion protein mAnxB1ScuPA, structure and application thereof |
| 02/09/2011 | CN101967193A Hsp60 fragment capable of being combined with LOX-1, derivatives thereof and use thereof |